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In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR) þ Reduced tacrolimus (TAC; n ¼ 245), TAC Control (n ¼ 243) or TAC Elimination (n ¼ 231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR þ Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference À2.2%, 97.5% confidence interval [CI] À8.8%, 4.4%). BPAR was less frequent in the EVR þ Reduced TAC group (6.1% vs. 13 .3% in TAC Control, p ¼ 0.010). Adjusted change in estimated glomerular filtration rate (eGFR) from randomization to month 24 was superior with EVR þ Reduced TAC versus TAC Control: difference 6.7 mL/min/1.73 m 2 (97.5% CI 1.9, 11.4 mL/min/1.73 m 2 , p ¼ 0.002). Among patients who remained on treatment, mean (SD) eGFR at month 24 was 77.6 (26.5) mL/min/ 1.73 m 2 in the EVR þ Reduced TAC group and 66.1 (19. 3) mL/min/1.73 m 2 in the TAC Control group (p < 0.001). Study medication was discontinued due to adverse events in 28.6% of EVR þ Reduced TAC and 18.2% of TAC Control patients. Early introduction of everolimus with reduced-exposure tacrolimus at 1 month after liver transplantation provided a significant and clinically relevant benefit for renal function at 2 years posttransplant.
Introduction
Minimizing exposure to calcineurin inhibitors (CNIs) following solid organ transplantation is a well-established clinical objective. Use of mammalian target of rapamycin (mTOR) inhibitors to support CNI minimization is a highly promising approach, but it remains unclear whether long-term maintenance of low-exposure CNI therapy or CNI elimination is a preferable strategy. Data from kidney transplantation suggest that although CNI reduction can be undertaken without loss of efficacy in the presence of the mTOR inhibitor everolimus (1) , tubulointerstitial and glomerular damage continues in the presence of reduced CNI exposure (2) . Experience with the use of everolimus to minimize CNI exposure following liver transplantation is more limited and is largely related to CNI-free regimens. One prospective (3) and one retrospective (4) study in maintenance liver transplant patients have suggested that the benefit of conversion to everolimus from CNI therapy appears to be concentrated in patients with greater residual renal function at the time of conversion (3, 4) . Two randomized trials have explored early switch from CNI to everolimus therapy in liver transplantation (5, 6) . Masetti et al. (5) observed significantly higher renal function in patients maintained on everolimus monotherapy from day 30 versus cyclosporine with mycophenolate mofetil. In the PROTECT study, conversion from tacrolimus or cyclosporine to everolimus (with or without steroids) over an 8-week period starting on day 30 resulted in higher renal function at 12 months posttransplant based on the fourvariable Modification of Diet in Renal Disease (MDRD4) formula without loss of efficacy (6) .
In a prospective trial, 719 patients were randomized at 1 month after liver transplantation to continue a standard tacrolimus-based regimen or start everolimus with reduced-exposure tacrolimus or tacrolimus elimination. The primary results at month 12 posttransplant have been reported previously (7) . Following completion of the entire 24-month study, the current manuscript focuses on the evolution of renal function from randomization to month 24 posttransplant.
Methods

Study design
This was a 24-month prospective, randomized, multicenter, three-arm, parallel-group, open-label study in de novo liver transplant recipients undertaken at transplant centers in 19 countries in Europe, North America and South America and other countries including Australia, Russia and Israel during January 2008 to April 2012.
After a run-in period during which the immunosuppression regimen was identical for all groups, patients were randomized at 30 (AE5) days posttransplant in a 1:1:1 ratio to one of three treatment groups: (i) EVR þ Reduced TAC; (ii) TAC Control or (iii) TAC Elimination. Patients were stratified prior to randomization according to pretransplant hepatitis C virus (HCV) status and quartiles of renal function (based on estimated glomerular filtration rate [eGFR] according to the MDRD4 formula (8) ). Randomization to the TAC Elimination arm was stopped in April 2010, when approximately 690 patients had been randomized in total. This followed a recommendation from the independent Data Monitoring Committee based on a significantly higher rate of acute rejections leading to study discontinuation clustered around the time of tacrolimus withdrawal versus the other two treatment arms. The study protocol was amended to stop recruitment to the TAC Elimination arm, and eligible patients were subsequently randomized equally between the EVR þ Reduced TAC and TAC Control groups. Patients already randomized to TAC Elimination who were 180 days postrandomization were converted to standard treatment, whereas those who were >180 days postrandomization with stable graft function could continue on their assigned TAC Elimination regimen.
The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and all patients provided written informed consent.
Study endpoints
The primary efficacy endpoint was the composite efficacy failure rate of treated biopsy-proven acute rejection (tBPAR), graft loss or death since randomization. tBPAR was defined as treated acute rejection with rejection activity index (RAI) !3 according to Banff 1997 criteria (9) . The key secondary endpoint was the change in renal function from randomization as assessed by eGFR using the MDRD4 formula (10) . These endpoints were revised from the original endpoints after implementation of the protocol amendment. The original co-primary endpoints were noninferior composite efficacy failure rate of death, graft loss or loss to follow-up, and superior renal function (as assessed by eGFR using the MDRD4 formula).
Inclusion and exclusion criteria
Adult (18-70 years) recipients of a primary full-size liver transplant from a deceased donor who had received tacrolimus and corticosteroids (with or without mycophenolic acid) from time of transplant were eligible to enter the run-in period. Key inclusion criteria at the time of randomization comprised (i) eGFR (MDRD4) !30 mL/min/1.73 m 2 ; (ii) acceptable graft function (aspartate aminotransferase [AST], alanine aminotransferase [ALT] and total bilirubin levels 3 times the upper limit of normal, with alkaline phosphatase 5 times the upper limit of normal) and (iii) tacrolimus trough concentration !8 ng/mL in the week prior to randomization. Key exclusion criteria included hepatocellular carcinoma (HCC) that did not fulfill Milan criteria (11, 12) as per explant histology, and receipt of antibody induction therapy. To enter the runin period, patients were also excluded if urine protein excretion was !1.0 g/ day. At the point of randomization, key additional inclusion criteria were: Doppler ultrasound showing the patency of hepatic artery, hepatic and portal veins; confirmation of eGFR !30 mL/min/1.73 m 2 ; and absence of acute rejection requiring T cell depleting antibody therapy or !1 episode of steroidsensitive rejection during the run-in period.
Immunosuppression
In the EVR þ Reduced TAC arm, everolimus therapy was initiated at a dose of 1.0 mg b.i.d. within 24 h of randomization, adjusted from day 5 to target a trough (C 0 ) concentration in the range 3-8 ng/mL. Once everolimus trough concentration was within this range, tacrolimus dose was tapered to achieve a trough concentration of 3-5 ng/mL by week 3 after randomization. In the TAC Control arm, the target tacrolimus trough concentration was 8-12 ng/ mL until month 4 posttransplant and 6-10 ng/mL thereafter. In the TAC Elimination arm, everolimus was administered as in the EVR þ Reduced TAC group until month 4 posttransplant, when the target trough concentration range had to be increased to 6-10 ng/mL. Tacrolimus elimination was then started and was to be completed by the end of month 4 posttransplant.
Corticosteroids were to be initiated in all patients at the time of transplant and administered according to local practice (including peri-operative intravenous corticosteroids), with a minimum oral dose of 5 mg prednisolone/day after randomization to be continued until at least month 6 posttransplant. Mycophenolic acid, if used, was administered as per local practice but had to be discontinued by the time of randomization.
Statistical analysis
No inferential statistical comparisons were undertaken for the TAC Elimination group due to premature discontinuation of recruitment and extensive conversion of patients in this arm to standard therapy.
The primary endpoint of composite efficacy failure at month 12 was analyzed based on a noninferiority test with a prespecified 12% noninferiority margin at a one-sided 0.0125 significance level. The incidence of the composite efficacy failure endpoint was estimated using the Kaplan-Meier productlimit formula and standard error (SE) based on Greenwood's formula. The incidence rates of the composite efficacy failure endpoint at month 24, as well as its components at months 12 and 24, were also estimated based on the Kaplan-Meier method. The key secondary endpoint of change in eGFR (MDRD4) from randomization to month 12 was analyzed using an analysis of covariance (ANCOVA) model, with treatment group, pretransplant HCV status and eGFR (MDRD4) at randomization as covariates. Based on this model, a noninferiority test was performed with a noninferiority margin of À6 mL/min/1.73 m 2 at a one-sided 0.0125 significance level. A similar ANCOVA analysis was performed for the change in eGFR from randomization to month 24.
Efficacy and renal function analyses were based on the intent-to-treat (ITT) population, comprising all randomized patients. On-treatment renal function (eGFR) analyses were carried out as supportive analyses, and included eGFR values taken up to 2 days after study drug discontinuation. Safety analyses other than renal function were performed on the safety population, which included all randomized patients who received at least one dose of randomized study drug.
Results
Patient population
The (71.9%) discontinued study medication prematurely, including patients up to 180 days postrandomization who converted to standard treatment according to the protocol amendment. In total, 202, 204 and 174 patients in the EVR þ Reduced TAC, TAC Control and TAC Elimination groups, respectively, completed the 24-month study (141, 164 and 65 on study medication at 24 months; Figure 1 ). The treatment groups were well balanced in terms of risk factors for chronic renal failure, including age, gender, pretransplant HCV infection and the incidence of diabetes (Table 1) .
Immunosuppression
In the EVR þ Reduced TAC group, tacrolimus tapering began after everolimus whole blood trough levels were confirmed to be in the target range (3-8 ng/mL). Immediately after initiation of everolimus (month 1), median C 0 tacrolimus levels declined, reaching 5.7 and 5.2 ng/mL, respectively, at months 2 and 3. From month 6 onwards median C 0 tacrolimus trough levels remained below 5.0 ng/ mL reaching 4.5 ng/mL at month 12 and 3.8 ng/mL at month 24 ( Figure S1 ). Table 2 ). The incidence of BPAR at month 24 was significantly lower in the EVR þ Reduced TAC group versus the TAC Control group (Kaplan-Meier incidence rate 6.1% vs. 13.3%, p ¼ 0.010; Table 2 ). By month 24, moderate or severe BPAR had occurred in no EVR þ Reduced TAC patients and in 10 TAC Control patients.
The incidence of tBPAR ( Figure 2B ) was numerically lower in the EVR þ Reduced TAC group. Graft loss and/or death was similar in the two treatment groups (Table 2) .
Estimated GFR
Mean eGFR (MDRD4) was similar between the EVR þ Reduced TAC and TAC Control groups at the point of randomization (Table 1) . eGFR in the EVR þ Reduced TAC Noninferiority test with noninferiority margin of 12%; p < 0.001. 4 BPAR episodes occurring prior to randomization were excluded. KM, Kaplan-Meier.
arm was statistically superior to the TAC Control arm from 1 month after randomization until the end of the 24-month study, although the difference in favor of the EVR þ Reduced TAC arm reduced slightly from months 12 to 24 ( Figure 3A ; Table S1 ). Table 3 ).
The evolution of renal function from randomization to month 24 was better in the EVR þ Reduced TAC group versus TAC Control when estimated using the MDRD4, CKD-EPI, Nankivell and Cockcroft-Gault formulae (Figure 4 Table S2 ). The evolution of eGFR over 2 years posttransplant was similar in the TAC Elimination group to the EVR þ Reduced TAC group in the ITT population ( Figure 3A) . Based on ANCOVA analysis, the difference in adjusted change in eGFR (MDRD4) from randomization for the TAC Elimination group versus TAC Control was 9. Patients were stratified according to HCV serology status at time of randomization. Among patients for whom eGFR data were available at randomization and month 24, the mean (SD) change in the EVR þ Reduced TAC group was À8.1 (24.5) mL/min/1.73 m 2 in HCV-negative patients versus À1. 6 (33.8) Estimated GFR: on-treatment analysis In a pre-planned analysis, on-treatment eGFR was also evaluated using eGFR values up to 2 days after study drug discontinuation. As in the ITT population, eGFR in the EVR þ Reduced TAC group was significantly higher than in the TAC Control arm by 1 month after randomization and thereafter (all p < 0.001; Figure 3B ). At month 24, mean (SD) eGFR (MDRD4) for patients who remained ontreatment was 77. 6 (26.5) Other renal function parameters Mean (SD) serum creatinine level was similar between the EVR þ Reduced TAC and TAC Control groups at randomization, but significantly lower in the EVR þ Reduced TAC cohort at month 24 (Table 3) . During the period from randomization to month 24, renal replacement therapy was required by seven patients in the EVR þ Reduced TAC arm, eight patients in the TAC Control group and four patients in the TAC Elimination arm (2.9%, 3.3% and 1.7%, respectively).
Proteinuria (defined as 1.0 to <3.0 g/day) was present in four EVR þ Reduced TAC patients and one TAC Control patient at randomization and in five and three patients, respectively, at month 24. Proteinuria was reported as an adverse event in nine and two patients, respectively (p ¼ 0.063). Nephrotic syndrome (!3.0 g/day) was present in no EVR þ Reduced TAC patients and one TAC Control patient at randomization, and in no patients at month 24.
The urine protein to creatinine ratio became slightly higher in the EVR þ Reduced TAC group versus TAC Control by month 4 in the ITT population ( Figure S2A ), but for patients on-treatment the difference was not significant ( Figure S2B -10 370] ) but remained below 300 mg/g in both treatment arms at all times after randomization. Of the 10 patients in the EVR þ Reduced TAC group who had urine protein to creatinine ratio !500 mg/g at randomization, six showed a subsequent decline, three did not provide a postrandomization value, and the remaining patient had a ratio of 2254 mg/g at baseline and 3646 mg/g at month 18 with no value recorded at month 24.
Cystatin C levels were similar at randomization (Table 1) and at month 24, when mean (SD) values were 1.3 (0.4) mg/L in both the EVR þ Reduced TAC and TAC Control groups.
Safety
Over the 24-month study period, the overall rates of adverse events (96.3% in the EVR þ Reduced TAC group and 97.9% in the TAC Control group) and serious adverse events (56.3% and 54.1%, respectively) were similar between groups. Hyperlipidemia, neutropenia, peripheral edema, stomatitis/mouth ulceration and thrombocytopenia were more frequent in the EVR þ Reduced TAC arm, while renal failure excluding proteinuria was more frequent in the TAC Control group ( 
Discussion
This is the first trial to report outcomes at 2 years in liver transplant recipients randomized to reduced-exposure TAC or TAC Elimination versus a standard TAC Control group. The results demonstrate that renal function, as assessed by eGFR, was superior at 2 years after liver transplantation in patients randomized to EVR þ Reduced TAC at 1 month posttransplant versus those receiving a standard tacrolimus regimen. The superior renal function in the EVR þ Reduced TAC arm was achieved without a penalty in terms of efficacy: Comparable efficacy results versus the TAC Control group at month 24 were confirmed despite very low TAC concentrations (3-5 ng/mL). Indeed, significantly fewer BPAR events were observed with EVR þ Reduced TAC versus the TAC Control arm. Although enrollment into the TAC Elimination arm was discontinued prematurely and many patients were converted back to standard treatment, the relatively smaller number of patients who remained on a 
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Wilcoxon rank sum test for EVR þ Reduced TAC vs. TAC Control. CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated glomerular filtration rate; MDRD4, four-variable Modification of Diet in Renal Disease; SD, standard deviation.
Mean change in eGFR from randomization to month 24 (mL/min/1.73m 2 or mL/min)
12
MDRD4
EVR+Reduced TAC TAC Control TAC Elimination tacrolimus-free regimen showed strikingly good renal function at month 24.
The effect of treatment on renal function was apparent early after randomization, with the difference reaching significance by the first month (7) and peaking around month 4. In the first 3-4 months after randomization, eGFR remained largely unchanged in the EVR þ Reduced TAC group but declined in the standard tacrolimus arm until reaching a plateau at a level approximately 10 mL/min/ 1.73 m 2 lower than in the EVR þ Reduced TAC cohort. Although this difference narrowed somewhat during months 12-24 in the ITT population, the difference between the two groups in adjusted change of eGFR from randomization to month 24 was 6.7 mL/min/1.73 m 2 , a benefit that can be considered clinically relevant. Interestingly, the difference in eGFR at month 24 for ontreatment patients was 11.5 mL/min/1.73 m 2 in favor of EVR þ Reduced TAC, reflecting the impact of patients being discontinued from study medication in the EVR þ Reduced TAC arm and then receiving higher doses of CNI. In the TAC Control arm the reverse was observed: A greater proportion of patients with tacrolimus exposure below the recommended target range appeared beneficial to renal function in the ITT population ( Figure 3B ). Impaired renal function at 1 year after liver transplantation is predictive of subsequent deterioration and poor kidney function at 5 years (13) (14) (15) , so it would seem likely that a benefit in renal function might be sustained long term although this remains speculative.
It was notable that among those patients who remained on their randomized treatment, the difference in mean eGFR between the EVR þ Reduced TAC group versus the control group (11.5 mL/min/1.73 m 2 ) was more marked than in the overall ITT population ( Figure 3B) . Results of this preplanned on-treatment analysis provide a more accurate assessment of the potential renal effects of an everolimusbased low-CNI regimen.
A clear separation in tacrolimus exposure and a substantial overall reduction of 39% was achieved in the EVR þ Reduced TAC arm compared to TAC Control. Median C 0 tacrolimus trough levels were below 6.0 ng/mL as early as month 1 after randomization and were consistently below 5.0 ng/mL from month 5 postrandomization onward, suggesting that the recommended target ranges for both everolimus 3-8 ng/mL and tacrolimus 3-5 ng/mL were achieved in the majority of EVR þ Reduced TAC patients. Given the very low rate of BPAR in the EVR þ Reduced TAC arm, further reduction to even lower tacrolimus exposure ranges might be feasible after introduction of everolimus and could be justified in order to minimize CNIrelated toxicity.
Premature discontinuation of recruitment to the TAC Elimination arm, and switching of patients less than 6 months postrandomization to standard therapy, necessarily limits interpretation of renal function in this group. However, eGFR data were provided at month 24 by 57 patients who continued to receive their assigned tacrolimus-free treatment regimen throughout the study. higher than the standard TAC group. Although relatively fewer patients were maintained on the CNI-free regimen up to month 24 compared to the number of patients in the other two treatment groups who completed the 2-year study, this marked renal benefit does suggest that tacrolimus elimination with everolimus introduction at month 1 after liver transplantation could be a potentially valuable strategy for preserving renal function. Further characterization of patients who may be suitable candidates for an everolimus-based, CNI-free regimen is required, as is exploration of different partner drugs (e.g. mycophenolic acid) and the optimal procedure for conversion based on the current findings and those of previous trials of CNI elimination (5, 6) .
There was no significant difference in the rate of wound healing events between the EVR þ Reduced TAC and the TAC Control arms (11.0% vs. 8.3%, respectively) , although it should be borne in mind that the study was not powered to detect differences in relatively infrequent adverse events. In kidney transplantation, recent studies which have employed a similar regimen of concentration-controlled everolimus with reduced-exposure CNI therapy to that used here have reported no association with an increased rate of wound healing complications (1, 16) . Moreover, in the current trial introduction of everolimus was delayed until day 30, avoiding the period of highest risk for healing complications related to the initial transplant procedure. Bacterial infections, while numerically higher in the EVR þ Reduced TAC arm, did not differ significantly and the overall rate of infection was similar between the two groups.
Nephrotic proteinuria was rare. The mean urine protein to creatinine ratio was slightly higher in the EVR þ Reduced TAC arm versus the TAC Control group, a difference that was significant in the ITT population but not among patients who remained on treatment. It remained below the subnephrotic range throughout the study with only 1 of the 10 patients with overt proteinuria (!500 mg/day) at randomization experiencing worsening proteinuria during the study. Overall, aggravation of proteinuria in maintenance liver (17) and kidney (18, 19) transplant patients after conversion to mTOR inhibitors, particularly in patients with significant existing proteinuria, does not seem as concerning in the de novo liver transplant setting. Nevertheless, careful monitoring of proteinuria in future studies, over longer follow-up periods, is important.
The study design included several features that merit consideration.
Use of an open-label design was mandated by the need for careful adjustments in everolimus and tacrolimus exposure. The absence of blinding, however, would not have influenced laboratory measurements of renal function. Stratification according to HCV status and renal function at the time of randomization helped to achieve balance between the treatment arms in terms of the likely evolution of renal function (20, 21) . The control regimen-tacrolimus with steroids either continued or withdrawn not earlier than 6 months posttransplantrepresents a standard immunosuppressive regimen after liver transplantation, although addition of mycophenolic acid (particularly during the early posttransplant period to facilitate lower tacrolimus exposure) has become increasingly widespread since the study protocol was developed.
Introduction of everolimus at day 30 and exclusion of patients without patent hepatic vasculature by hepatic Doppler ultrasound were considered appropriate strategies to minimize the possible risk of transplant-related wound healing events and hepatic artery thrombosis reported using sirolimus in de novo liver transplant recipients. For the assessment of renal function, eGFR is known to be less reliable than direct measurements (22, 23) but multiple methods of estimating GFR were used to confirm the findings obtained with the MDRD4 formula and showed consistent results. In terms of generalizability, the study population showed similar eGFR values at the time of randomization to those seen in the general liver transplant population (13) .
In conclusion, results from this randomized trial demonstrate that introduction of everolimus with reduced-exposure tacrolimus at 1 month after liver transplantation achieves robust preservation of renal function at 2 years posttransplant with no compromise in efficacy. These results mirror findings at 1 year (7), with no marked changes in efficacy or safety profile during months 12-24. While elimination of tacrolimus at 4 months posttransplant was associated with an increased rate of acute rejection, those patients who remained on the tacrolimus-free regimen at 2 years exhibited excellent renal function, with mean eGFR approximately 20 mL/min/1.73 m 2 higher than in the standard-tacrolimus group.
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